| Literature DB >> 35603207 |
Anton V Tyurin1, Milyausha K Salimgareeva2, Ildar R Miniakhmetov2,3, Rita I Khusainova2,3, Alexandr Samorodov4, Valentin N Pavlov5, Julia Kzhyshkowska6,7,8.
Abstract
The immune system is severely compromised in patients with COVID-19. The representative group of 43 patients were selected from the cohort of 342 patients with COVID-19 and pneumonia. This group of 43 patients was examined for the levels of C-reactive protein, biomarker of systemic inflammation, and for the subsets of adaptive immune cells. The immunological parameters were correlated with the metabolic parameters and cardiovascular pathology history. We identified that a decrease in the absolute number of T-lymphocytes, T-cytotoxic, T-activated and B-lymphocytes correlated with the higher levels of CRP. The absolute number of T-helpers and the absolute number of double positive T-lymphocytes positively correlated with the levels of iron in serum (Z= 0,310 and Z=0,394). The absolute numbers of T-activated lymphocytes positively correlated with serum levels of LDH (Z = 0,422), ferritin (Z = 0,407) and iron (Z = 0,418). When studying subpopulations of lymphocytes, depending on the combined pathology, we found that the absolute numbers of B-lymphocytes and double positive T-lymphocytes in the peripheral blood were significantly reduced in patients with arterial hypertension (p=0,0074 and p=0,0227, correspondingly). The increased levels of NK cell were found in patients with a history of coronary heart disease (p=0,0108). In addition, we found that deficiencies in the adaptive immune system correlated with the deficiencies in iron metabolism. The cardiovascular pathology upsets the balance in the adaptive and innate immune system in the circulation of patient with severe COVID-19.Entities:
Keywords: C-reactive protein; COVID-19; cardiovascular pathology; lymphocytes; metabolic syndrome; systemic inflammation
Mesh:
Substances:
Year: 2022 PMID: 35603207 PMCID: PMC9120577 DOI: 10.3389/fimmu.2022.856883
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Basic characterisation of total COVID-19 patients’ cohort and cohort selected for the lymphocyte analysis.
| Parameter | Normal value | Total sample N= 342; Me (Q1-Q3) | Immunophenotyped sample N= 43; Me (Q1-Q3) |
|---|---|---|---|
| Age, years | 59,00 (48,0- 67,0) | 60,0 (50,0-69,0) | |
| Hospitalization, days | 12,00 (10,0-14,0) | 9,0 (8,0-12,0) | |
| Before hospitalization, days | 7,00 (5,0-9,0) | 7,0 (5,0-10,0) | |
| Leukocytes, 1 * 106 / l | 4,0-9,0 | 5,10 (3,7-7,0) | 4,84 (4,02-6,75) |
| Platelets, 1* 103 / l | 150-400 | 195,0 (157,0-252,0) | 180,0 (143,0-229,0) |
| Erythrocytes, 1 * 1012 / l | 3,5-5,5 | 4,6 (4,26-4,88) | 4,48 (4,18-4,72) |
| Neutrophils, % | 40-70 | 71,4 (61,2-78,4) | 62,5 (54,8-73,5) |
| Lymphocytes, % | 19-45 | 23,2 (15,7-31,7) | 24,0 (19,5-34,3) |
| Neutrophils / Lymphocytes ratio | 2,47±0,65 | 3,08 (1,89-4,84) | 2,58 (1,64-3,68) |
| CRP, mg / l | 0-9 | 44,9 (24,4-73,7) | 29,6 (18,0-60,0) |
| Creatinine, μmol / l | 44-124 | 91,7 (83,0-104,0) | 95,6 (80,2-105,5) |
| AST, Unit | 2-35 | 29,4 (22,3-42,2) | 25,6 (20,4-34,8) |
| ALT, Unit | 4-41 | 26,5 (18,6-43,3) | 26,5 (18,1-33,8) |
| KFK, Ed | 2-171 | 122,5 (70,0-234,0) | 111,0 (73,0-163,0) |
| LDH, Unit | 5-480 | 360,0 (301,0-449,0) | 323,0 (264,0-430,0) |
| Iron, μmol / l | 6,6 - 26 | 8,0 (5,2-12,2) | 11,0 (6,1-17,0) |
| Ferritin, mcg / l | 20 - 250 | 380,2 (188,1-631,4) | 287,0 (156,05-540,5) |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; KFK, creatine phosphokinase; LDH, lactate dehydrogenase.
Clinical and laboratory characteristics of COVID-19 patients divided into 3 groups according to the CRP levels.
| Parameter | Normal value | C-RP <10mg/ lGr. 1 N=17Me (Q1 -Q3) | C-RP 10-50mg/l Gr. 2 N=16Me (Q1 -Q3) | C-RP >51mg/l Gr. 3 N=10Me (Q1 -Q3) |
|---|---|---|---|---|
| Age, years | 58,0 (44,0-69,0) | 58,50 (49,5-62,5) | 63,0 (60,0-70,0) | |
| Diabetes | 1 (5,8%) | 3 (18,7%) | 0 | |
| Hypercholesterolemia | 3 (17,6%) | 0 | 0 | |
| Arterial hypertension | 8 (47,0 %) | 7 (43,7%) | 7 (70,0%) | |
| Coronary artery disease | 3 (17,6%) | 2 (12,5%) | 2 (20,0%) | |
| Cerebrovascular disease | 7 (41,1%) | 2 (12,5%) | 4 (40,0%) | |
| Hospitalization, days | 8,0 (8,0-9,0) | 9,50 (8,0-11,0)*** | 13,0 (10,0-14,0)** | |
| Before hospitalization, days | 8,0 (6,0-10,0) | 5,50 (4,0-8,5) | 5,5 (4,0-12,0) | |
| BMI, kg/m2, M±SD | 18,5-24,99 | 28,45±5,65 | 28,43±3,16 | 30,07±5,71 |
| Leukocytes, 1 * 106 / l | 4,0-9,0 | 4,84 (4,5-6,11) | 4,99 (4,1-5,95) | 5,14 (3,66-7,85) |
| Platelets, 1* 103 / l | 150-400 | 215,0 (180,0-257,0)* | 171,00 (142,5-209,5) | 152,5 (98,0-188,0)** |
| Erythrocytes, 1 * 1012 / l | 3,5-5,5 | 4,3 (4,07-4,87) | 4,66 (4,21-4,69) | 4,4 (4,19-4,62) |
| Neutrophils, % | 40-70 | 57,8 (51,5-62,0) | 64,80 (53,9-74,65) | 73,0 (63,1-74,6)** |
| Lymphocytes, % | 19-45 | 32,5 (29,4-35,8)* | 21,80 (18,95-33,15) | 20,25 (19,1-23,3)** |
| N / L ratio | 2,47±0,65 | 1,81 (1,43-2,34) | 2,86 (1,75-3,96) | 3,543 (2,68-3,9)** |
| Lymph. / CRP ratio | – | 6,5 (5,8-7,16)* | 1,23 (0,84-2,12)*** | 0,309 (0,22-0,40)** |
| CRP, mg / l | 0-9 | 5,2 (2,9-7,31)* | 18,25 (12,0-26,31)*** | 67,54 (57,7-78,0)** |
| Creatinine, μmol / l | 44-124 | 87,0 (76,5-101,1) | 96,20 (81,2-104,75) | 104,7 (95,6-123,8) |
| AST, Unit | 2-35 | 26,8 (20,4-34,8) | 24,20 (19,45-33,75) | 27,4 (24,1-45,1) |
| ALT, Unit | 4-41 | 27,0 (17,2-28,1) | 29,50 (19,75-44,45) | 24,3 (19,5-28,2) |
| KFK, Ed | 2-171 | 106,0 (67,0-137,0) | 107,50 (74,0-170,5) | 142,0 (122,0-163,0) |
| LDH, Unit | 5-480 | 295,0 (251,0-340,0) | 311,50 (260,5-416,0) | 435,0 (354,0-561,0)** |
| Iron, μmol / l | 6,6 - 26 | 12,0 (11,2-18,6) | 10,95 (7,25-17,8)*** | 6,0 (5,8-6,6)** |
| Ferritin, mcg / l | 20 - 250 | 152,0 (65,3-238,0)* | 407,55 (293,8-671,9) | 541,2 (403,7-564,3)** |
* level p <0.05 Gr. 1 vs Gr. 2; ** level p <0.05 Gr. 1 vs Gr. 3; *** level p <0.05 Gr. 2 vs Gr. 3.
Figure 1Content of lymphocyte subpopulations depending on CRP levels in patients with COVID-19. Venous blood out of 43 patients was analyzed using flow cytometry to identify SUBP1 – total lymphocytes (CD45 bright), SUBP2 - B-cells (CD3-CD19+), SUBP3 - T-cells (CD3+CD19-), SUBP4 - T-helpers (CD3+CD4+CD8-), SUBP5 - T-cytotoxic (CD3+CD8+CD4-), SUBP6 - T-NK cells (CD3+CD56+), SUBP7 - double positive T-lymphocytes (CD4+CD8+), SUBP8 - True natural killer cells (CD3-CD56+), SUBP9 - activated T cells (CD3+HLA-DR+). COVID-19 patients were divided in 3 groups according to the CRP levels: group 1 <10 mg/l; group 2 10-50 mg/l; group 3 >50 mg/l. Statistical analysis was carried out using Mann-Whitney test.
Figure 2Analysis of correlations of serum concentrations of lactate dehydrogenase, iron and ferritin with lymphocyte subpopulations. 16 ml of whole venous blood out of 43 patients was analyzed to measure lactate dehydrogenase, iron and ferritin levels and lymphocyte subpopulation count. Biochemical analysis was carried out by the colorimetric method, lymphocyte subpopulations studied by flow cytometry. Statistical analysis to find the relationship between these parameters was carried out according to Spearman test. (A) intersection of correlations between biochemical parameters and lymphocyte subpopulations. (B) revealed positive (upward axis) and negative (downward axis) correlations between lymphocyte subpopulations and biochemical parameters.
Figure 3Comparative analysis of lymphocyte subpopulations in patients with associated clinical conditions. Clinical conditions associated with metabolic syndrome - arterial hypertension, overweight, hypercholesterolemia, diabetes mellitus, coronary and cerebral artery disease - were assessed in the study group. For all examined subjects, lymphocyte subpopulations were assessed by flow cytometry. A comparative analysis of lymphocyte subpopulations in patients in the studied groups was carried out; statistical analysis was carried out using the Mann-Whitney test.